Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in the detection of cognitive impairment that could identify dementias, including Alzheimer’s disease (AD). If effective, the AI tool could potentially be developed to support the early detection and staging of cognitive impairment and dementia, leading to appropriate additional testing for the clinical, biological diagnosis and treatment of dementias such as AD. [Read more…] about Geisinger and Eisai to test real-world validity of AI-powered Passive Digital Marker (PDM) in detecting early cognitive impairment and dementia
Welcome to a new edition of SharpBrains’ e‑newsletter, featuring eight timely scientific and industry news plus a few fun teasers to appreciate our unique human brains.
“None of us thinks that our beliefs and attitudes are incorrect; if we did, we obviously wouldn’t hold those beliefs and attitudes. Yet, despite our sense that we are usually correct, we must accept that our views may sometimes turn out to be wrong. This kind of humility isn’t simply virtuous—the research suggests that it results in better decisions, relationships, and outcomes. So, the next time you feel certain about something, you might stop and ask yourself: Could I be wrong?”
#3. Should older politicians, and other leaders, undergo cognitive testing? The debate continues … here are some good comments from the online debate we had last summer:
- PRO: “Definitely. We routinely screen applicants for a wide range of jobs. Apply for the police, you will be tested. Join the military, you will be evaluated. Should we not know if a candidate for the highest position in the country has a serious emotional, intellectual or psychological impairment?”
- CON: “I disagree because these tests are very bad at predicting how good someone would be in leading a country. It doesn’t require the ability to store a lot of information in your working memory. Being a good leader requires only one essential thing: having the right priorities.”
- IT DEPENDS: “Who makes the test? What cognitive metrics do we use? The biases in that design could lead to significant unexpected or even intentionally skewed results.”
What a year for Click and for digital therapeutics!
The road to heaven is paved with good decisions…
“The word psychedelic means ‘mind-manifesting,’ but what has been missing is useful ‘mind-imaging’—the ability to dynamically trace the neural correlates of human conscious experience. Conventional neuroimaging just isn’t dynamic enough to study the psychedelic experience in the brain as it happens. This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding” — Dr. Alex Belser, Cybin’s Chief Clinical Officer
“analyzing EEGs is labor intensive and interpretation of these tests can vary from one clinician to another..…Beacon Biosignals has assembled what it claims is one of the world’s largest clinical EEG databases. By applying its proprietary machine-learning algorithms to the database, the company says it has identified neurobiomarkers—biological indicators that are associated with certain groups of patients, drug activity, and therapeutic efficacy.”
Not good, yet completely predictable, and let’s remember this is for a “treatment” costing as much as $100,000/ year with exactly ZERO proven clinical benefit: “…The researchers found 425 cases in the combined aducanumab group experienced ARIA (41.3%), and ARIA-edema was identified in 362 patients or 35.2%. Of them, 94 (26%) had symptoms, such as headache, confusion, dizziness and nausea. They found ARIA-microhemorrhage and ARIA-superficial siderosis in 197 patients (19.1%) and 151 patients (14.7%), respectively.”
Q: What does, “you must come and visit us sometime!” actually mean?
Wishing you and yours a Happy & Healthy Hanukkah, December and Christmas,
The SharpBrains Team
Electroencephalography is a decades-old technique for capturing brain activity, data that are used to evaluate brain disorders. Beacon Biosignals is applying artificial intelligence to these tests, and the neurotechnology startup has found a ready market in pharmaceutical companies interested in assessing how their experimental brain therapies are working. Now Beacon Biosignals has something else: $27 million in financing. [Read more…] about Beacon Biosignals raises $27M to scale EEG, AI-based neurobiomarker discovery platform
Belfast-based Cumulus raises €6.9m for its ‘Fitbit for the brain’ (The Irish Times):
… Formerly known as BrainWaveBank, the company has developed a wireless electroencephalogram (EEG) headset and proprietary software platform that use advanced analytics and machine learning to measure cognitive fitness.
“This funding will allow us to build on the ground-breaking advances we have made in remote, frequent monitoring of brain activity and cognitive function in the home, in partnership with leading developers of digital biomarkers,” said Mr Cunningham, the company’s chief executive. [Read more…] about Cumulus Neuroscience raises $8.3M to develop EEG-based wireless ‘Fitbit for the brain’
The Rise of Big Data Psychiatry (The Wall Street Journal):
As a physician, I need to figure out three things when a new patient walks into my office: what their life is typically like, what has changed that made them seek treatment and what I can do to help them. It’s a complex problem, and most fields of medicine approach it by taking measurements. If I were a cardiologist evaluating a patient’s chest pain, for instance, I would speak with the patient, but then I would listen to their heart and measure their pulse and blood pressure. I might order an electrocardiogram or a cardiac stress test, tools that weren’t available a century ago.
Because I’m a psychiatrist, however, I evaluate patients in precisely the same way that my predecessors did in 1920: I ask them to tell me what’s wrong, and while they’re talking I carefully observe their speech and behavior. But psychiatry has remained largely immune to measurement. At no point in the examination do I gather numerical data about the patient’s life or behavior, even though tools for taking such measurements already exist. In fact, you likely are carrying one around in your pocket right now. Keep reading essay HERE, adapted from the new book Reading Our Minds: The Rise of Big Data Psychiatry by psychiatrist Daniel Barron. [Read more…] about Reading Our Minds: New book issues strong call to action to modernize psychiatry
FDA Releases Artificial Intelligence/Machine Learning Action Plan (FDA press release):
Today, the U.S. Food and Drug Administration released the agency’s first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach to advance the Agency’s oversight of AI/ML-based medical software … The AI/ML-Based Software as a Medical Device Action Plan outlines five actions that the FDA intends to take, including:
- Further developing the proposed regulatory framework, including through issuance of draft guidance on a predetermined change control plan (for software’s learning over time);